Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Teva
Israel - Petach Tikva
TETRABENAZINE (tetrabenazine) by Teva is vesicular monoamine transporter 2 inhibitors [moa]. Approved for vesicular monoamine transporter 2 inhibitor [epc]. First approved in 2017.
Drug data last refreshed 23h ago
Vesicular Monoamine Transporter 2 Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Worked on TETRABENAZINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo